COO

In its upcoming report, The Cooper Companies (COO) is predicted by Wall Street analysts to post quarterly earnings of $1.11 per share, reflecting an increase of 0.9% compared to the same period last year. Revenues are forecasted to be $1.1 billion, representing a year-over-year increase of 3.6%. Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock. While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights. Given this perspective, it's time to examine the average forecasts of specific The Cooper Companies metrics that are routinely monitored and predicted by Wall Street analysts. The consensus among analysts is that 'Revenue by Category- CVI' will reach $742.19 million. The estimate suggests a change of +3.3% year over year. Analysts predict that the 'Revenue by Category- CSI' will reach $356.69 million. The estimate indicates a change of +4.3% from the prior-year quarter. It is projected by analysts that the 'Revenue by Category- CSI- Office and surgical' will reach $213.77 million. The estimate suggests a change of +4.4% year over year. Analysts expect 'Revenue by Category- CSI- Fertility' to come in at $143.32 million. The estimate indicates a year-over-year change of +4.5%. Analysts forecast 'Revenue by Category- CVI- Sphere, other' to reach $367.10 million. The estimate indicates a change of +2.1% from the prior-year quarter. The average prediction of analysts places 'Revenue by Category- CVI- Toric and multifocal' at $375.41 million. The estimate points to a change of +4.6% from the year-ago quarter. According to the collective judgment of analysts, 'Revenue by Geography- Americas' should come in at $305.98 million. The estimate points to a change of +7% from the year-ago quarter. Based on the collective assessment of analysts, 'Revenue by Geography- Asia Pacific' should arrive at $134.25 million. The estimate indicates a year-over-year change of -4.3%. The combined assessment of analysts suggests that 'Revenue by Geography- EMEA' will likely reach $303.55 million. The estimate points to a change of +3.9% from the year-ago quarter. View all Key Company Metrics for The Cooper Companies here>>> Shares of The Cooper Companies have demonstrated returns of -6.8% over the past month compared to the Zacks S&P 500 composite's +2.5% change. With a Zacks Rank #4 (Sell), COO is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Over the last six months, CooperCompanies’s shares have sunk to $75.74, producing a disappointing 9.5% loss - a stark contrast to the S&P 500’s 12.9% gain. This may have investors wondering how to approach the situation. Is now the time to buy CooperCompanies, or should you be careful about including it in your portfolio? Get the full stock story straight from our expert analysts, it’s free. Even with the cheaper entry price, we don’t have much confidence in CooperCompanies. Here are three reasons why COO doesn’t excite us, plus one stock we’d rather own. We at StockStory place the most emphasis on long-term growth, but within healthcare, a stretched historical view may miss recent innovations or disruptive industry trends. CooperCompanies’s recent performance shows its demand has slowed as its annualized revenue growth of 6.5% over the last two years was below its five-year trend. We’re wary when companies in the sector see decelerations in revenue growth, as it could signal changing consumer tastes aided by low switching costs. Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite. Over the next 12 months, sell-side analysts expect CooperCompanies’s revenue to rise by 4.2%, a slight deceleration versus its 9.7% annualized growth for the past five years. This projection is underwhelming and suggests its products and services will see some demand headwinds. Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? A company’s ROIC explains this by showing how much operating profit it makes compared to the money it has raised (debt and equity). CooperCompanies historically did a mediocre job investing in profitable growth initiatives. Its five-year average ROIC was 4.6%, lower than the typical cost of capital (how much it costs to raise money) for healthcare companies. CooperCompanies isn’t a terrible business, but it doesn’t pass our bar. Following the recent decline, the stock trades at 15.9× forward P/E (or $75.74 per share). While this valuation is fair, the upside isn’t great compared to the potential downside. We’re pretty confident there are superior stocks to buy right now. We’d recommend looking at the most entrenched endpoint security platform on the market. ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies. Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE. Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.

Staar Surgical (STAA) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +47.62%. A quarter ago, it was expected that this maker of implantable lenses would post earnings of $0.13 per share when it actually produced earnings of $0.38, delivering a surprise of +192.31%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Staar Surgical, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $93.54 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 3.05%. This compares to year-ago revenues of $44.32 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Staar Surgical shares have added about 8% since the beginning of the year versus the S&P 500's gain of 12.9%. While Staar Surgical has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Staar Surgical was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #1 (Strong Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.12 on $80.17 million in revenues for the coming quarter and $0.62 on $333.92 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, The Cooper Companies (COO), is yet to report results for the quarter ended July 2026. The results are expected to be released on September 9. This surgical and contact lens products maker is expected to post quarterly earnings of $1.11 per share in its upcoming report, which represents a year-over-year change of +0.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. The Cooper Companies' revenues are expected to be $1.1 billion, up 3.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STAAR Surgical Company (STAA) : Free Stock Analysis Report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Cooper Companies' share price has fallen about 33% over the past five years, and with the stock now around US$70.31, the valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Over the past five years, Cooper Companies has delivered a cumulative shareholder loss of roughly 33%, which raises the bar for the current price to be supported by future earnings and cash flows. For long term valuation, the key support may come from Cooper Companies' ability to sustain profitable growth in its core businesses. A major risk is that profitability or cash generation falls short of what the current share price already factors in. Cooper Companies passes only 2 of 6 valuation checks, which points to a stock that leans expensive on the broader metrics rather than one that stands out as clearly undervalued. The issue now is whether Cooper Companies' current valuation and recent track record leave enough upside potential to compensate for the risks investors are taking on at this price. Cooper Companies delivered -5.7% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry. For Cooper Companies, the P/E ratio is a useful lens because earnings are a central driver of how investors are currently valuing the stock. The shares trade on a P/E of about 58.2x, which is more than double the Medical Equipment industry average of roughly 26.7x and well above the peer group average of about 23.4x. That places Cooper Companies at a clear premium to many companies in its sector. A tailored fair P/E ratio for Cooper Companies, taking into account its characteristics relative to the industry and broader market, is around 35.2x. The current 58.2x multiple sits far above this fair level, so a lot of optimism around future earnings appears to be reflected in the price already. At this valuation, Cooper Companies needs its earnings profile to justify a premium that is significantly higher than both the industry and the modelled fair multiple. On the P/E metric, Cooper Companies stock screens as overvalued relative to both its industry and a more tailored fair multiple. See what the numbers say about this price — find out in our valuation breakdown. Simply Wall St Narratives for Cooper Companies are meant to connect this valuation puzzle to clear, testable assumptions about the company's future growth, margins and earnings, showing what would need to happen for the stock to be worth materially more or less than today's price. They sit on the stock's Community page. Rather than relying on a single multiple or model, each one lays out its own fair value assumptions so you can see how they hold up as new results come through. The community is split on Cooper Companies, with one camp seeing meaningful upside and the other treating the current price as more than full. Bull case: 13% undervalued Read the full Bull Case to see why Cooper Companies could be undervalued Bear case: 9% overvalued Read the full Bear Case to see why Cooper Companies could be overvalued Do you think there's more to the story for Cooper Companies? Head over to our Community to see what others are saying! For Cooper Companies, the current market multiple points to a stock that screens as overvalued rather than clearly cheap. The key question from here is whether earnings and cash generation can develop in a way that ultimately supports such a premium to peers. If you think Cooper Companies can translate its investments and execution into durable profitability that keeps justifying a higher P/E, today’s pricing may make sense. If not, the risk is that the multiple does the heavy lifting now and later settles back if those expectations do not hold. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include COO. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

San Ramon, California-based The Cooper Companies, Inc. (COO) is a global medical device company that develops and manufactures products for vision care, women's health, and fertility and surgical procedures. With a market capitalization of approximately $13.7 billion, the company operates through its two business units, CooperVision and CooperSurgical, serving healthcare professionals and patients in more than 130 countries while helping improve eye care and reproductive health outcomes worldwide. COO is set to report its Q3 earnings soon. Ahead of the release, analysts expect the company to report diluted EPS of $1.11, up marginally from $1.10 in the year-ago quarter. However, COO has surpassed Wall Street's EPS estimates in each of the past four quarters, which is impressive. Dear SpaceX Stock Fans, Mark Your Calendars for July 23 Microsoft Earnings Preview: Get Ready for Soaring AI Spending to Sink MSFT Stock Why Nvidia (NVDA) Stock Faces Sell-the-News Risk Following Its Q2 Earnings Report Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For fiscal 2026, analysts expect the company to report EPS of $4.63, up 12.4% from $4.12 in fiscal 2025. Moreover, its EPS is expected to increase by another 7.8% to $4.99 in fiscal 2027. COO stock has declined 4.3% over the past 52 weeks, underperforming both the S&P 500 Index ($SPX), which returned 16.5%, and the State Street Health Care Select Sector SPDR ETF (XLV), which climbed 18.5% during the same period. Cooper Companies has trailed the broader market over the past year as investors have grown cautious about its slowing growth outlook. While the company has continued to expand, its revenue growth has trailed many healthcare peers, and analysts expect sales growth to moderate further over the next year. Additionally, below-average returns on invested capital have raised concerns about the company's ability to generate strong returns from its investments, weighing on investor sentiment. Analysts remain somewhat bullish on COO, with the stock earning a consensus "Moderate Buy" rating. Among the 17 analysts covering the stock, nine recommend a "Strong Buy," one rates it a "Moderate Buy," six recommend a "Hold," and one suggests a “Strong Sell.” The average price target of $81 implies a potential upside of 15.3% from the current share price. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

The Cooper Companies, Inc. COO posted second-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.21, up 26.0% year over year and beat the Zacks Consensus Estimate of $1.10 by 10.0%. Operational improvements have driven bottom-line growth. GAAP loss per share for the quarter was 40 cents, significantly down from the year-ago period’s GAAP EPS of 44 cents, affected by a litigation-related charge tied to the resolution of claims associated with a December 2023 voluntary product recall at CooperSurgical. Revenues totaled $1.08 billion, up 8% year over year on a reported basis and up 5% organically. The figure topped the Zacks Consensus Estimate of $1.05 billion by 2.6%. The quarterly revenues were up 5% year over year at constant exchange rate (CER). The top-line growth was driven by steady demand across CooperVision and CooperSurgical, alongside new product launches and continued operating discipline. Shares of COO were up 5.3% in after-hours trading following the earnings call. The company’s shares have lost 24.3% in the year-to-date period compared with the industry’s 10.4% decline. However, the S&P 500 Index was up 10.3% during the same period. Image Source: Zacks Investment Research COO conducts its business via two reportable segments — CooperVision (“CVI”) and CooperSurgical (“CSI”). COO delivered record quarterly revenues as both operating segments contributed to growth. For the second quarter of fiscal 2026, the CVI segment’s revenues totaled $723.5 million, up 8% year over year on a reported basis and 4% at CER as well as organically. This figure compares to our segmental projection of $711 million. Growth was supported by strong sales of MyDay and MiSight, combined with rising sales of Biofinity, torics and multifocals. MyDay lenses continued its double-digit growth rate. Biofinity grew 5% organically, while MiSight delivered strong growth of 24%. However, softness in Clariti lens sales continued in the fiscal second quarter as the global contact lens market continues to trend toward premium offerings, which included MyDay offerings. Category-wise, CVI derives revenues from Toric and multifocal, Sphere and others. In the fiscal second quarter, Toric and multifocal revenues totaled $364.9 million, up 11% year over year on a reported basis, and up 7% organically as well as at CER. This figure compares to our projection of $355 million. Sphere and other revenues totaled $358.6 million, up 5% year over year on a reported basis and up 1% at CER as well as organically. This figure compares to our projection of $354 million. The CSI segment’s revenues totaled $358 million, which moved up 8% on a reported basis and 6% at CER and organically. This figure compares to our projection of $344 million. Growth was driven by strength across the global fertility portfolio, including strong demand for capital equipment in the United States and continued momentum from Witness, the company's automated lab tracking system. Additional support came from distributor restocking activity in the Middle East following the reopening of airspace. Category-wise, CSI derives revenues from Office and surgical, and Fertility. In the fiscal second quarter, Office and Surgical revenues totaled $214.2 million, up 4% on a reported and organic basis as well as at CER. This figure compares to our projection of $209 million. PARAGARD delivered flat revenues year over year. Medical devices grew 6%, led by the strong performance of the surgical OB/GYN portfolio and continued momentum in specialty surgical products. Fertility revenues in the fiscal second quarter amounted to $143.8 million, up 13% on a reported basis and up 10% organically and at CER year over year, supported by improving cycles and increasing investments in technology and workflow optimization by fertility clinics. This figure compares to our projection of $134 million. Geographically, CVI derives revenues from the Americas, Europe and the Asia Pacific. However, performance was anchored by continued momentum in the Americas and EMEA. Americas’ revenues totaled $303.2 million, up 7% year over year on a reported basis and 7% at CER and organically. The growth was driven by continued strength in premium lenses. The figure compares to our projection of $302 million. EMEA revenues amounted to $289.7 million, up 17% year over year on a reported basis and up 6% at CER and organically. Fueled by strong demand for MyDay and MiSight, the company continued to be the leader in the region for both revenue and wearers. This figure compares to our projection of $275 million. Asia Pacific revenues in the fiscal second quarter totaled $130.6 million, down 6% year over year, as well as organically and at CER. Portfolio repositioning, including the rationalization of legacy hydrogel products and weaker-than-expected demand in Japan, more than offset contributions from new launches. This figure compares to our projection of $131 million. In the quarter under review, Cooper Companies’ adjusted gross profit rose 7.9% to $736.1 million. However, the adjusted gross margin was 68.1%, roughly flat year-over-year as positive currency offset higher costs, including tariffs. We had projected a 66.7% gross margin for the fiscal second quarter. Selling, general and administrative expenses rose 69.5% to $676.2 million. Research and development expenses decreased 6.6% to $42.5 million. Adjusted operating costs totaled $438.9 million, reflecting a 1.5% increase from the prior-year quarter’s level. Adjusted operating profit totaled $297.2 million, reflecting a 19.1% increase from the year-earlier quarter’s level. The adjusted operating margin in the fiscal second quarter expanded 260 bps to 27.5%, supported by efficiencies from last year’s reorganization and tight operating expense growth. COO exited the second quarter of fiscal 2026 with cash and cash equivalents of $138.8 million compared with $124.9 million at the end of the first quarter of fiscal 2026. Total debt at the end of the fiscal second quarter was $2.46 billion compared with $2.5 billion at the end of the first quarter of fiscal 2026. Cooper Companies has updated its outlook for fiscal 2026. The company now expects revenues in the range of $4,285-$4,321 million (down from prior guidance of $4,306-$4,346 million), suggesting an organic improvement of 3.5-4.5% from the prior-year figure. The Zacks Consensus Estimate is pegged at $4.32 billion. COO expects the CVI segment’s revenues in the range of $2,883-$2,908 million (down from prior guidance of $2,906-$2,932 million), suggesting an organic improvement of 3.5-4.5% from the year-earlier registered figure. The company anticipates the CSI segment’s revenues in the band of $1,402-$1,414 million (up from prior guidance of $1,400-$1,413 million), indicating an organic improvement of 4-5% from the year-earlier figure. For the entire fiscal year, adjusted EPS is expected in the $4.58-$4.66 range. The Zacks Consensus Estimate is pegged at $4.62. The Cooper Companies, Inc. price-consensus-eps-surprise-chart | The Cooper Companies, Inc. Quote Cooper Companies delivered strong results in the second quarter of fiscal 2026, marking its tenth consecutive earnings beat. Performance was driven by both businesses, as CooperVision benefited from continued demand for premium daily silicone hydrogel lenses, particularly MyDay, while MiSight revenues surged 24% amid strong adoption in Japan and Europe. CooperSurgical also posted solid results, led by growth in fertility, supported by strength in capital equipment, genomics and consumables. The company further expanded operating margins through ongoing efficiency initiatives and back-office consolidation, while generating robust free cash flow. Looking ahead, CooperVision is expected to benefit from continued adoption of premium lenses, expansion of MiSight, new product launches and improved execution across Asia Pacific. The company is advancing its Clariti portfolio, with upcoming launches of next-generation multifocal in EMEA and Asia Pacific and the toric and multifocal launch in Japan. CooperSurgical remains well positioned to capitalize on healthy fertility trends, growing IVF access and increasing investments by clinics in technology and workflow optimization. Management also highlighted significant interest in CooperSurgical as part of its strategic review, which could unlock additional shareholder value. However, weak consumer demand in Japan and China, combined with the ongoing rationalization of legacy hydrogel products, is expected to pressure Asia Pacific results through the remainder of fiscal 2026. Tariffs, foreign exchange headwinds and higher operating costs could also weigh on margins. Despite these challenges, management maintained its earnings outlook and raised free cash flow expectations. COO currently has a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are West Pharmaceutical WST, Globus Medical GMED and Intuitive Surgical ISRG. West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here. West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%. Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%. Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%. Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

The Cooper Companies (COO) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $0.96 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +9.67%. A quarter ago, it was expected that this surgical and contact lens products maker would post earnings of $1.03 per share when it actually produced earnings of $1.1, delivering a surprise of +6.8%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. The Cooper Companies, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $1.08 billion for the quarter ended April 2026, surpassing the Zacks Consensus Estimate by 2.57%. This compares to year-ago revenues of $1 billion. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. The Cooper Companies shares have lost about 26.4% since the beginning of the year versus the S&P 500's gain of 10.4%. While The Cooper Companies has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for The Cooper Companies was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.18 on $1.12 billion in revenues for the coming quarter and $4.62 on $4.32 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the broader Zacks Medical sector, Icon PLC (ICLR), is yet to report results for the quarter ended March 2026. This contract research organization is expected to post quarterly earnings of $2.86 per share in its upcoming report, which represents a year-over-year change of -10.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Icon PLC's revenues are expected to be $2 billion, down 0% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report ICON PLC (ICLR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

SAN RAMON, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2026. Second quarter 2026 revenue of $1.082 billion, up 8%, or up 5% organically, from last year's second quarter. Second quarter 2026 GAAP diluted earnings per share (EPS) of $(0.40), down $0.84 from last year's second quarter driven by a litigation-related charge to resolve outstanding claims associated with a December 2023 voluntary product recall at CooperSurgical. Second quarter 2026 Non-GAAP diluted EPS of $1.21, up $0.25 or 26% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. "We delivered a strong second quarter, achieving record revenue and non-GAAP earnings per share while marking our tenth consecutive quarter of exceeding consensus earnings expectations," said Al White, CooperCompanies' President and CEO. "Our performance reflects solid execution across our businesses, supported by new product launches, favorable demand drivers, and ongoing focus on operational discipline. In addition, we have reached agreements to resolve substantially all of the claims related to CooperSurgical's fertility media recall, representing an important step in addressing this issue and allowing us to move forward with our strategic review. Moving forward, we are focused on driving sustainable, profitable growth and strong cash flow, while maintaining discipline in a dynamic operating environment." Second Quarter Operating Results Revenue of $1.082 billion, up 8% from last year’s second quarter, up 5% in constant currency, up 5% organically. Gross margin of 68% similar to last year's second quarter. On a non-GAAP basis, gross margin was also similar to last year at 68%, with positive FX offsetting higher costs including tariffs. Operating margin of negative 3% compared with 18% in last year’s second quarter, primarily reflecting higher SG&A expenses, due to a $271.6 million litigation-related charge. On a non-GAAP basis, operating margin was up 260 basis points from last year to 27%, reflecting disciplined execution and meaningful synergies from last year's reorganization. Interest expense of $20.9 million compared with $24.2 million in last year's second quarter driven by lower interest rates and lower average debt. On a non-GAAP basis, interest expense was $20.9 million, down from $23.5 million. Cash provided by operations of $182.8 million, offset by capital expenditures of $86.4 million resulted in free cash flow of $96.4 million. Second Quarter CooperVision (CVI) Revenue Revenue of $723.5 million, up 8% from last year’s second quarter, up 4% in constant currency, up 4% organically. Revenue by category: Revenue by geography: Second Quarter CooperSurgical (CSI) Revenue Revenue of $358.0 million, up 8% from last year's second quarter, up 6% in constant currency, up 6% organically. Revenue by category: Other During the second quarter, the Company repurchased $13.1 million of common stock, approximately 174 thousand shares, at an average share price of $75.84. The program has $860.8 million of remaining availability. Recorded a $271.6 million net pre-tax charge within SG&A related to certain product-related litigation matters associated with a December 2023 voluntary recall of embryo culture media at CooperSurgical, consisting of $324.1 million of accrued litigation liabilities, partially offset by $52.5 million of expected insurance recoveries. Fiscal Year 2026 Financial Guidance The Company updated its fiscal year 2026 financial guidance. Details are summarized as follows: Fiscal 2026 total revenue of $4.285 - $4.321 billion (organic growth of 3.5% to 4.5%) Fiscal 2026 non-GAAP diluted EPS of $4.58 - $4.66 Reaffirm previously communicated long-term free cash flow objective exceeding $2.2 billion for fiscal years 2026 through 2028 Non-GAAP diluted earnings per share guidance excludes amortization and impairment of intangible assets, and certain income or gains and charges or expenses including acquisition and integration costs which we may incur as part of our continuing operations. With respect to the Company’s guidance expectations, the Company has not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses, which are reconciling items between the non-GAAP and GAAP measures. Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, the Company is not able to provide such guidance. Reconciliation of Selected GAAP Results to Non-GAAP Results To supplement our financial results and guidance presented on a GAAP basis, we provide non-GAAP measures such as non-GAAP gross margin, non-GAAP operating margin, non-GAAP diluted earnings per share, as well as constant currency and organic revenue growth because we believe they are helpful for the investors to understand our consolidated operating results. Management uses supplemental non-GAAP financial measures internally to understand, manage and evaluate our business, to make operating decisions, and to plan and forecast for future periods. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. We provide further details of the non-GAAP adjustments made to arrive at our non-GAAP measures in the GAAP to non-GAAP reconciliations below. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. To present constant currency revenue growth, current period revenue for entities reporting in currencies other than the United States dollar are converted into United States dollars at the average foreign exchange rates for the corresponding period in the prior year. To present organic revenue growth, we excluded the effect of foreign currency fluctuations and the impact of any acquisitions, divestitures and discontinuations that occurred in the comparable period. We define the non-GAAP measure of free cash flow as cash provided by operating activities less capital expenditures. We believe free cash flow is useful for investors as an additional measure of liquidity because it represents cash that is available to grow the business, make strategic acquisitions, repay debt, or buyback common stock. Management uses free cash flow internally to understand, manage, make operating decisions and evaluate our business. In addition, we use free cash flow to help plan and forecast future periods. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. EPS, amounts and percentages may not sum or recalculate due to rounding. (1) There were no acquisition and integration-related charges in the three and six months ended April 30, 2026. The acquisition and integration-related charges in fiscal 2025 were primarily related to the obp Surgical and Cook Medical acquisition and integration expenses. Charges included $3.5 million and $4.8 million related to redundant personnel costs for transitional employees, $1.1 million and $2.4 million of professional services fees, $1.2 million and $2.1 million of inventory fair value step-up amortization, $1.1 million and $1.8 million of facility rationalization costs, and $0.3 million and $0.4 million of other acquisition and integration-related activities in the three and six months ended April 30, 2025. The three months ended April 30, 2025 also included $2.4 million of acquisition-related non-cash cumulative true-up adjustments reflecting changes in compensation. Charges in this category may include the direct effects of acquisition accounting, such as amortization of inventory fair value step-up, professional services fees, regulatory fees, and items related to integrating acquired businesses, such as redundant personnel costs for transitional employees, acquisition-related non-cash cumulative true up adjustments reflecting changes in compensation, other acquisition-related costs, integration-related professional services, long-lived asset write-offs, manufacturing integration costs, legal entity and facility rationalization, and other integration-related activities. (2) There were no charges related to the exit of business in the three months ended April 30, 2026. The six months ended April 30, 2026 included $1.7 million of specifically-identified long-lived asset write-offs and $0.1 million of other costs related to product line exits. There were no exit of business charges in the three and six months ended April 30, 2025. Charges in this category may include costs related to product line exits such as inventory write-offs, employee severance costs, and specifically-identified long-lived asset write-offs. (3) Charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations and the E.U. in vitro diagnostic medical device regulation (collectively, the "Medical device regulations") for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be limited to a specific time period. (4) Charges included $1.1 million and $2.3 million of redundant personnel costs for transitional employees in the three and six months ended April 30, 2026. The six months ended April 30, 2026 also included $0.4 million of employee severance costs and $0.3 million of other business optimization charges. There were no business optimization charges in the three and six months ended April 30, 2025. Charges in this category represent costs associated with initiatives to increase efficiency and optimize the cost structure, and may include, among other items, changes to our IT infrastructure and operations, employee severance costs, redundant personnel costs for transitional employees, legal entity and other business reorganizations, and inventories associated with the business optimization activities. (5) Charges included $4.5 million and $11.2 million related to legal matters and $0.9 million and $1.8 million of gains and losses on minority interest investments in the three and six months ended April 30, 2026. The three months ended April 30, 2026 also included $272.2 million related to litigation expense and associated legal costs. Charges in the three months ended April 30, 2025 included $16.7 million of gains and losses on minority interest investments, of which $15.7 million was related to loss on disposal of a minority interest investment, and $0.7 million of accretion of interest attributable to acquisition installment payables. Charges in the six months ended April 30, 2025 included $17.9 million of gains and losses on a minority interest investment, $1.4 million of accretion of interest attributable to acquisition installment payables, and $0.6 million legal fees. Charges in this category may include legal matters, litigation expense, and other items that are not part of ordinary operations. The adjustments to arrive at non-GAAP net income also include gains and losses on minority interest investments and accretion of interest attributable to acquisition installment payables. (6) In fiscal 2021, the Company transferred its CooperVision intellectual property and goodwill to its UK subsidiary. As a result, we recorded a deferred tax asset equal to approximately $2.0 billion as a one-time tax benefit in accordance with U.S. GAAP in fiscal 2021 as subsequently adjusted for changes in UK tax law. The non-GAAP adjustments reflect the ongoing net deferred tax benefit from tax amortization each period under UK tax law. Audio Webcast and Conference Call The Company will host an audio webcast today for the public, investors, analysts and news media to discuss its second quarter results and current corporate developments. The audio webcast will be broadcast live on CooperCompanies' website, www.investor.coopercos.com, at approximately 5:00 PM ET. It will also be available for replay on CooperCompanies' website, www.investor.coopercos.com. Alternatively, you can dial in to the conference call at 800-715-9871; conference ID 6529381. About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com. Forward-Looking Statements This earnings release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including our fiscal year 2026 financial guidance, are forward looking. In addition, all statements regarding anticipated growth in our revenues, expected savings from reorganization activities, anticipated effects of any product recalls, anticipated market conditions, planned product launches, restructuring or business transition expectations, regulatory plans, and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; the impact of international conflicts, including the ongoing conflict in the Middle East, and the global response to international conflicts on the global and local economy, financial markets, energy markets, currency rates and our ability to supply product to, or through, or around, affected countries; our substantial and expanding international operations and the challenges of managing an organization spread throughout multiple countries and complying with a variety of legal, compliance and regulatory requirements; the actual imposition or threats of tariffs, customs duties and fees by the U.S. government and other nations in response and other retaliatory actions, such as trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers, as well as the impact of the Company’s efforts to mitigate the effects of such tariffs or similar measures; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our net sales and earnings; our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds; changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income; acquisition-related adverse effects including the failure to successfully achieve the anticipated net sales, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms); compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of personal information such as the Health Insurance Portability and Accountability Act of 1996 and the California Consumer Privacy Act in the U.S. and the General Data Protection Regulation requirements in Europe, including but not limited to those resulting from data security breaches; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain due to challenges associated with integration of acquisitions, man-made or natural disasters, pandemic conditions, cybersecurity incidents or other causes; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to the failure to perform by third-party vendors, including cloud computing providers or other technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades; a successful cybersecurity attack which could interrupt or disrupt our information technology systems, or those of our third-party service providers, or cause the loss of confidential or protected data; market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry specifically and the medical device or pharmaceutical industries generally, including but not limited to the EU Medical Devices Regulation (MDR) and the EU In Vitro Diagnostic Medical Devices Regulation; legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes, or other litigation; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions; reduced sales, loss of customers, reputational harm and costs and expenses, including from claims and litigation related to product recalls and warning letters; failure to receive, or delays in receiving, regulatory approvals or certifications for products; failure of our customers and end users to obtain adequate coverage and reimbursement from third-party payers for our products and services; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets and idle manufacturing facilities and equipment; the success of our research and development activities and other start-up projects; dilution to earnings per share from acquisitions or issuing stock; impact and costs incurred from changes in accounting standards and policies; risks related to environmental laws and requirements applicable to our facilities, products or manufacturing processes, including evolving regulations regarding the use of hazardous substances or chemicals in our products; risks related to environmental, social and corporate governance issues, including those related to regulatory and disclosure requirements, climate change and sustainability; and other events described in our United States Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2025, as such Risk Factors may be updated in annual and quarterly filings. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any obligation to update or revise them except as required by law. Contact: Kim DuncanVice President, Investor Relations and Risk [email protected] EPS, amounts and percentages may not sum or recalculate due to rounding.

For the quarter ended April 2026, The Cooper Companies (COO) reported revenue of $1.08 billion, up 7.9% over the same period last year. EPS came in at $1.21, compared to $0.96 in the year-ago quarter. The reported revenue represents a surprise of +2.57% over the Zacks Consensus Estimate of $1.05 billion. With the consensus EPS estimate being $1.10, the EPS surprise was +9.67%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how The Cooper Companies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue by Geography- Americas: $303.2 million compared to the $302.16 million average estimate based on two analysts. The reported number represents a change of +7.4% year over year. Revenue by Geography- Asia Pacific: $130.6 million versus $130.83 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -5.8% change. Revenue by Geography- EMEA: $289.7 million versus $275.45 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +16.5% change. Revenue by Category- CVI: $723.5 million compared to the $710.74 million average estimate based on five analysts. The reported number represents a change of +8.1% year over year. Revenue by Category- CSI: $358 million compared to the $343.62 million average estimate based on five analysts. The reported number represents a change of +7.6% year over year. Revenue by Category- CSI- Office and surgical: $214.2 million compared to the $208.84 million average estimate based on four analysts. The reported number represents a change of +4.1% year over year. Revenue by Category- CSI- Fertility: $143.8 million versus the four-analyst average estimate of $133.94 million. The reported number represents a year-over-year change of +13.3%. Revenue by Category- CVI- Sphere, other: $358.6 million versus $354.32 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.1% change. Revenue by Category- CVI- Toric and multifocal: $364.9 million compared to the $354.71 million average estimate based on four analysts. The reported number represents a change of +11.1% year over year. View all Key Company Metrics for The Cooper Companies here>>> Shares of The Cooper Companies have returned -1.3% over the past month versus the Zacks S&P 500 composite's +4.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in The Cooper Companies, Inc.? Here are five stocks we like better. Cooper Companies delivered a strong Q2 with record revenue of $1.08 billion and non-GAAP EPS of $1.21, marking its 10th straight quarter of beating consensus expectations. Management also said consolidated revenue grew 5% organically. CooperSurgical’s strategic review is moving ahead after the company settled more than 95% of claims tied to the 2023 embryo culture media recall. CEO Albert White said there is “robust interest” in CooperSurgical and the company is working quickly to determine the best path to maximize shareholder value. Guidance and cash generation were updated positively, with fiscal 2026 revenue now expected at $4.28 billion to $4.32 billion and free cash flow raised to about $650 million, while non-GAAP EPS guidance was maintained at $4.58 to $4.66. Management also signaled more aggressive share buybacks ahead, especially if CooperSurgical is sold. This ETF Weeds Out Small-Cap Underperformers Cooper Companies (NASDAQ:COO) reported record revenue and non-GAAP earnings for its fiscal second quarter of 2026, while management said it is advancing discussions with multiple parties interested in CooperSurgical as part of its strategic review. President and Chief Executive Officer Albert White said revenue rose 8% year over year to $1.08 billion, while non-GAAP earnings per share increased 26% to $1.21. White said the quarter marked the company’s 10th consecutive quarter of exceeding consensus earnings expectations. Chief Financial Officer and Treasurer Brian Andrews said consolidated revenue grew 5% organically. → Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for Investors Analysts Love These 3 Companies Reporting Earnings This Week “Overall, our results reflect steady execution against our strategy of driving sustainable, profitable growth through innovation, new product introductions, leveraging our infrastructure, generating free cash flow, and gaining market share,” White said. CooperVision revenue increased 8% to $724 million, or 4% organically, led by share gains in the Americas and EMEA. White said the Americas grew 7%, supported by strength in premium lenses, while EMEA rose 6% on demand for MyDay and MiSight. → Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit? 3 Oversold Stocks Flashing Bullish Reversal Signals Asia-Pacific revenue declined 6%, which management attributed to portfolio repositioning, including the rationalization of legacy hydrogel products, and broader market softness. White said weakness in Japan was greater than expected and that China also remained under pressure. During the question-and-answer session, White said the pressure in Asia-Pacific was “market-based” and tied to consumer weakness, especially in Japan and China. He said some markets in the region have more of a consumer-discretionary profile because contact lenses can be purchased without a prescription. White also noted some shift toward e-commerce, where CooperVision is less strong than in eye-care practitioner channels. → Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? Daily silicone hydrogel lenses grew 8%, with the MyDay brand delivering double-digit growth. White said Biofinity grew 5% organically, led by toric and multifocal lenses. MiSight, CooperVision’s pediatric myopia control product, grew 24% to $32 million. White said Japan is exceeding expectations for MiSight, while the launch of MyDay MiSight in Europe is performing “extremely well.” CooperSurgical revenue rose 8% to $358 million, or 6% organically. Fertility revenue increased 10% organically to $144 million, with strength in capital equipment, genomics and consumables. White cited U.S. strength and global momentum for RI Witness, CooperSurgical’s automated lab tracking system, as contributors to the quarter. White said fertility sales also benefited from late-quarter buy-in activity in the Middle East as distributors restocked after airspace reopened. He said underlying fertility trends remain healthy and that the business is expected to grow in the mid-single-digit range in the back half of the year. In the surgical products and services business, sales rose 4% to $214 million. Medical devices grew 6%, and PARAGARD revenue was flat, which White said was ahead of expectations. He noted that the prior-year comparison included the launch of the single-hand inserter. White said the company has reached settlements with substantially all claimants related to a December 2023 embryo culture media recall in the fertility business. Andrews said CooperSurgical voluntarily recalled one batch of embryo culture media consisting of three specific lots, which led to claims and lawsuits across multiple jurisdictions. Andrews said Cooper reached settlement agreements covering more than 95% of claimants and recorded a net charge of $271.6 million. That included $324.1 million of accrued settlement costs, partially offset by $52.5 million of insurance recoveries. The company excluded the charge from non-GAAP earnings. White said the resolution of the litigation allows Cooper to advance strategic discussions. He said the company has received “robust interest” in CooperSurgical and is working with its board and advisers to determine the best path to maximize shareholder value. In response to analyst questions, White said Cooper has received significant interest in both the entire CooperSurgical business and pieces of it, but that the company is currently proceeding based on interest in the entire business. He said there is “nothing now holding us back from being able to move very quickly” and indicated that an update could come before the next earnings call if progress is made. Andrews said non-GAAP gross margin was 68.1%, roughly flat from the prior year, as positive currency offset higher costs, including tariffs. Operating expenses increased 1%, reflecting benefits from the company’s reorganization. Operating income rose 19%, and operating margin was 27.5%. Free cash flow totaled $96 million in the quarter. Andrews said the company used cash to reduce net debt to $2.3 billion and repurchase $13 million of stock. White said buybacks were limited during the quarter but remain a core part of Cooper’s capital allocation strategy. Andrews said the company expects to be “much more aggressive” on share repurchases going forward after taking a conservative position during the quarter because of other activity. White also said that if CooperSurgical is sold, a significant portion of proceeds would likely be used for share buybacks, while the company would also evaluate the remaining company’s balance sheet. Cooper updated its fiscal 2026 revenue outlook to approximately $4.28 billion to $4.32 billion, reflecting 5% to 6% reported growth and 3.5% to 4.5% organic growth. CooperVision revenue is expected to be about $2.88 billion to $2.91 billion, up 5% to 6%, or 3.5% to 4.5% organically. CooperSurgical guidance was essentially unchanged at roughly $1.4 billion to $1.41 billion, up 4% to 5% as reported and organically. The company maintained non-GAAP EPS guidance of $4.58 to $4.66. Andrews said interest expense is expected to be around $85 million, with an effective tax rate of about 15.5%. Andrews also raised the fiscal 2026 free cash flow outlook to roughly $650 million, excluding litigation payouts, most of which are expected during fiscal 2026. He said the company still expects to generate $2.2 billion in free cash flow from 2026 through 2028, inclusive of expected litigation-related payments. Management said gross margins are expected to decline year over year, with third-quarter gross margin around 66%. Andrews attributed the pressure to unfavorable foreign exchange and higher costs, including tariffs and freight, as well as lower production at CooperVision as a new AI-enhanced inventory control system helps reduce inventory levels. Andrews said guidance assumes about $22 million of tariff impact this fiscal year and does not include potential tariff refunds. He said refunds could be as much as $15 million and would provide upside if received. Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women's health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry. The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Cooper Companies Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for June 2026.